Acid Fast Bacilli Smear (AFB)
Lung0 parametersReport in 12HrsAt Home
No Fasting Required
Details
Critical test in the diagnosis of tuberculosis (TB) and other mycobacterial infections
₹309₹450
31% OFF
FREE:AI Insights
Acid Fast Bacilli Smear (AFB) - Comprehensive Medical Test Guide
- Why is it done?
- Test Purpose: Detects acid-fast bacilli (AFB), primarily Mycobacterium tuberculosis, which causes tuberculosis (TB). The test identifies bacteria that have a waxy cell wall resistant to standard staining methods.
- Primary Indications: Suspected active tuberculosis, particularly pulmonary TB; evaluation of persistent cough lasting more than 3 weeks; screening in immunocompromised patients; monitoring of TB treatment response; investigation of hemoptysis or fever of unknown origin.
- Specimen Types: Sputum samples (early morning collections preferred); bronchoalveolar lavage (BAL); cerebrospinal fluid (CSF); urine; gastric washings; body fluids; or tissue samples depending on suspected infection site.
- Typical Timing: Performed urgently when TB is clinically suspected; routinely during initial evaluation of respiratory symptoms; serially during anti-TB therapy to assess treatment efficacy; at completion of therapy to confirm cure.
- Clinical Context: Essential for diagnosis of infectious tuberculosis; helps determine contagiousness of patients; guides infection control precautions; important for public health surveillance and contact tracing.
- Normal Range
- Normal Result: Negative (No acid-fast bacilli identified). This result is represented as "AFB Negative" or "No AFB seen." Indicates absence of acid-fast organisms in the specimen.
- Reporting Scale: Results are typically reported as: Negative (no AFB); 1+ (1-9 AFB per 100 fields); 2+ (10-99 AFB per 100 fields); 3+ (1-10 AFB per field); 4+ (>10 AFB per field on average).
- Units of Measurement: Semi-quantitative grading system; organisms per microscopic field; or descriptive reporting (rare, occasional, moderate, numerous).
- Normal Interpretation: Negative result typically rules out active infectious TB in respiratory specimens. However, one negative sputum does not exclude TB; minimum of 3-5 sputum samples collected on different days is recommended for adequate screening.
- Abnormal Results: Any positive finding (1+ through 4+) indicates presence of acid-fast organisms, suggesting active TB or other mycobacterial infections. Positive results require immediate confirmation with culture and drug susceptibility testing.
- Sensitivity and Specificity: AFB smear sensitivity ranges 40-80% depending on bacterial burden; specificity is high (>95%) for TB. Higher bacterial loads (3+ or 4+) indicate greater contagiousness.
- Interpretation
- Negative Result Interpretation: Suggests absence of acid-fast organisms in the specimen. In respiratory TB suspects, negative results do not exclude disease, especially in early infection, immunocompromised patients, or those with endobronchial lesions. Serial sampling (3-5 specimens over 2-3 days) increases detection sensitivity.
- 1+ Positive Result: One to nine acid-fast bacilli observed per 100 microscopic fields. Indicates low bacterial burden, typically associated with lower infectivity but still requires confirmation. Warrants repeat sampling and culture for definitive diagnosis.
- 2+ Positive Result: Ten to ninety-nine acid-fast bacilli per 100 fields. Indicates moderate bacterial burden with moderate infectivity. Strongly suggestive of active TB; warrants immediate patient isolation and initiation of anti-TB therapy pending culture confirmation.
- 3+ Positive Result: One to ten acid-fast bacilli per microscopic field. Indicates high bacterial burden with high infectivity. Strongly indicative of active contagious TB; patient poses significant transmission risk and requires immediate isolation and treatment initiation.
- 4+ Positive Result: More than ten acid-fast bacilli per microscopic field on average. Indicates very high bacterial burden with very high infectivity. Definitive evidence of active contagious TB; requires immediate airborne isolation, emergency treatment initiation, and aggressive infection control measures.
- Factors Affecting Interpretation: Specimen quality (sputum vs. saliva); collection timing (early morning samples more concentrated); number of samples submitted; patient's immune status; concurrent HIV infection; previous TB treatment history; current anti-TB therapy stage.
- Clinical Significance Patterns: Initial high positivity (3+ or 4+) that decreases during therapy indicates treatment response. Persistent or increasing positivity despite treatment suggests treatment failure or drug resistance. Negative conversion typically occurs within 2-3 weeks of appropriate therapy in drug-sensitive TB.
- Non-TB Mycobacteria: Positive AFB results may occasionally represent non-tuberculous mycobacteria (NTM) such as MAC or M. kansasii. Differentiation requires culture identification and species-specific testing, particularly important in HIV-positive patients.
- Extrapulmonary TB Considerations: In non-respiratory specimens (CSF, urine, lymph node), lower bacterial burdens are expected. Even rare AFB findings are clinically significant. Culture and molecular testing are particularly important for confirmation.
- Associated Organs
- Primary Organ System: Respiratory system (lungs and airways). Pulmonary TB accounts for ~85% of all TB cases. Infection typically begins in lung alveoli following inhalation of aerosolized droplets containing M. tuberculosis.
- Extrapulmonary Sites: Central nervous system (TB meningitis); lymphatic system (TB lymphadenitis); urogenital tract (renal TB); gastrointestinal tract (TB enteritis); bones and joints (TB osteomyelitis/arthritis); liver and spleen (TB hepatitis); adrenal glands; eyes (ocular TB).
- Conditions Associated with Positive Results: Active pulmonary tuberculosis; TB laryngitis; TB bronchitis; TB pleurisy; TB meningitis; miliary TB (disseminated); TB of lymph nodes, bones, joints, kidneys, and other organs; non-tuberculous mycobacterial infections (MAC, M. kansasii, M. abscessus).
- Risk Groups with High Positivity: HIV/AIDS patients (especially CD4 <50); immunosuppressed individuals; patients on TNF-alpha inhibitors; persons with diabetes; chronic kidney disease patients; elderly individuals; homeless and incarcerated populations.
- Complications of Untreated TB: Respiratory failure; massive hemoptysis; spontaneous pneumothorax; bronchopleural fistula; respiratory tract obstruction; progressive pulmonary fibrosis and cavitation; dissemination to multiple organs.
- Systemic Complications: Sepsis; multi-organ failure; acute respiratory distress syndrome (ARDS); immune reconstitution inflammatory syndrome (IRIS) in treated HIV patients; metabolic complications from prolonged illness.
- Transmission Risks: Positive sputum AFB smears indicate infectious disease; aerosol transmission occurs through coughing, sneezing, or speaking; close contacts and healthcare workers at risk; appropriate respiratory isolation is mandatory for positive cases.
- Latent TB Infection: Positive AFB indicates active disease, not latent infection. Individuals with latent TB infection will have negative AFB smears but positive tuberculin skin test or interferon-gamma release assay.
- Follow-up Tests
- Mycobacterial Culture: Gold standard for TB diagnosis; identifies M. tuberculosis and differentiates from NTM; allows drug susceptibility testing (DST); takes 2-8 weeks but essential for all positive AFB cases and for clinical management decisions.
- Nucleic Acid Amplification Tests (NAAT): Rapid molecular tests (Gene Xpert MTB/RIF); provides TB diagnosis within 2 hours; detects rifampicin resistance; WHO-recommended as initial diagnostic test; can be performed on various specimens.
- Drug Susceptibility Testing (DST): Determines resistance to first-line drugs (isoniazid, rifampicin); identifies multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB); critical for treatment regimen selection; performed on positive cultures.
- Chest X-ray: Evaluates extent of pulmonary involvement; identifies cavitary disease, infiltrates, or nodules; establishes baseline for treatment monitoring; performed at diagnosis and periodically during therapy.
- HIV Testing: Strongly recommended for all TB patients; determines if co-infection exists; affects treatment regimen selection and monitoring; essential for prognosis assessment and immune reconstitution risk stratification.
- Baseline Laboratory Tests: Complete blood count; liver function tests (ALT, AST, bilirubin); renal function (creatinine, BUN); baseline measurements for monitoring anti-TB drug toxicity during therapy.
- Serial AFB Smears During Treatment: Recommended monthly during initial intensive phase; serves to assess treatment response; demonstrates clearance of bacilli; 2-3 consecutive negative smears indicate completion of infectious period (usually within 2-3 weeks of appropriate therapy).
- Tuberculin Skin Test (TST) or Interferon-Gamma Release Assay: Used for latent TB screening; not helpful in active TB diagnosis but important for contact tracing and determining TB infection status in exposed individuals.
- Repeat Sputum Sampling: If initial AFB negative but clinical suspicion remains high; collection of 3-5 sputum samples on different days (preferably early morning) increases sensitivity; particularly important in immunocompromised patients.
- Imaging for Extrapulmonary TB: CT or MRI brain for TB meningitis suspicion; spinal imaging for TB spondylitis; abdominal ultrasound or CT for abdominal TB; based on clinical presentation and site of suspected infection.
- Contact Tracing Evaluation: TST or IGRA testing for household and occupational contacts; evaluation for active disease or latent infection; determination of need for preventive therapy in identified latent TB cases.
- Fasting Required?
- Fasting Requirement: No fasting is required for AFB smear testing. Food and water intake do not affect specimen quality or test results for this diagnostic test.
- Specimen Collection Preparation: For sputum samples, patient should rinse mouth with water (not mouthwash) to reduce oral contaminants. Collect specimen in sterile cup; early morning sputum (upon waking) preferred as it contains higher bacillary concentration.
- Special Instructions: Patient should cough deeply from lower respiratory tract to produce true sputum, not saliva; minimum 5-10 mL of sputum required; specimen must be clearly labeled with patient identification and collection date/time.
- Medications: No medications need to be discontinued specifically for AFB testing. Patients should continue all prescribed medications including any anti-TB therapy if already initiated. Bronchodilators may be helpful to facilitate sputum production if patient has difficulty.
- Specimen Storage and Transport: Sputum samples should be transported promptly to laboratory at room temperature (within 2-4 hours); refrigeration may be used if delay anticipated (up to 24 hours); specimens should not be frozen unless long-term storage needed.
- Safety Precautions: Collection should occur in well-ventilated area with respiratory droplet/airborne precautions; healthcare workers should wear appropriate PPE (N95 respirator); patient placement in negative pressure room if hospitalized to minimize transmission.
- Multiple Specimen Collection: Three to five sputum specimens recommended for optimal sensitivity (2-3 days collection); patients should space collections on different days; some settings use induced sputum if patient unable to produce spontaneous specimen.
- Other Specimen Types: If collecting non-sputum specimens (CSF, urine, BAL), standard specimen collection procedures apply; sterile containers required; prompt transport essential due to low bacillary concentration in these specimens.
- Patient Communication: Inform patient of importance of adequate specimen collection; explain droplet/airborne precautions and isolation requirements if positive result obtained; provide education regarding TB transmission, treatment adherence, and infection prevention.
How our test process works!
